journal article·2023-11Open access

A Cell‐Penetrant Peptide Disrupting the Transcription Factor CP2c Complexes Induces Cancer‐Specific Synthetic Lethality

Seung Han Son, Min Young Kim, Sungwoo Choi, Ji Sook Kim, Yong Sang Lee, Sangwon Lee, Yeon Ju Lee, Jin Youn Lee, Seol Eui Lee, Young Su Lim, Dae Hyun Ha, Eonju Oh, Young‐Bin Won, Chang‐Jun Ji, Mi Ae Park, Boram Kim, Kyu Tae Byun, Min Sung Chung, Jaemin Jeong, Dongho Choi, Eun Jung Baek, Eung‐Ho Cho, Sang‐Bum Kim, A. Reum Je, Hee‐Seok Kweon, Hyun Sook Park, Dongsun Park, June Sung Bae, Se Jin Jang, Chae‐Ok Yun, Ji Hyung Chae, Jin‐Won Lee, Su‐Jae Lee, Chan Gil Kim, Ho Chul Kang, Vladimir N. Uversky, Chul Geun Kim

Advanced Science· Volume 10· Issue 33

Abstract

Abstract Despite advances in precision oncology, cancer remains a global public health issue. In this report, proof‐of‐principle evidence is presented that a cell‐penetrable peptide (ACP52C) dissociates transcription factor CP2c complexes and induces apoptosis in most CP2c oncogene‐addicted cancer cells through transcription activity‐independent mechanisms. CP2cs dissociated from complexes directly interact with and degrade YY1, leading to apoptosis via the MDM2‐p53 pathway. The liberated CP2cs also inhibit TDP2, causing intrinsic genome‐wide DNA strand breaks and subsequent catastrophic DNA damage responses. These two mechanisms are independent of cancer driver mutations but are hindered by high MDM2 p60 expression. However, resistance to ACP52C mediated by MDM2 p60 can be sensitized by CASP2 inhibition. Additionally, derivatives of ACP52C conjugated with fatty acid alone or with a CASP2 inhibiting peptide show improved pharmacokinetics and reduced cancer burden, even in ACP52C‐resistant cancers. This study enhances the understanding of ACP52C‐induced cancer‐specific apoptosis induction and supports the use of ACP52C in anticancer drug development.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Cancer-related Molecular Pathways · RNA modifications and cancer · RNA Interference and Gene Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Life Science and Research Institute for Natural Sciences College of Natural Sciences Hanyang University Seoul 04763 South Korea

Department of Pathology Hanyang University College of Medicine Seoul 04763 South Korea

Department of Bioengineering College of Engineering Hanyang University Seoul 04763 South Korea

Department of Biotechnology and Research Institute for Biomedical and Health Science College of Biomedical and Health Science Konkuk University Chungju Chungbuk 27478 South Korea

Department of Surgery Hanyang University College of Medicine Seoul 04763 South Korea

Department of Laboratory Medicine Hanyang University College of Medicine Seoul 04763 South Korea

Department of Surgery Korea Institute of Radiological and Medical Sciences Seoul 01812 South Korea

Center for Research Equipment Korea Basic Science Institute Cheongju 28119 South Korea

CEFO Co. Ltd. Seoul 03150 South Korea

Department of Biology Education Korea National University of Education Cheongju Chungbuk 29173 South Korea

Department of Research and Development OncoClew Co. Ltd Seoul 04778 South Korea

Department of Pathology Asan Medical Center University of Ulsan College of Medicine Seoul 05505 South Korea

Asan Center for Cancer Genome Discovery Asan Institute for Life Sciences Seoul 05505 South Korea

Department of Molecular Medicine and USF Health Byrd Alzheimer`s Research Institute Morsani College of Medicine University of South Florida Tampa FL 33612 USA

CGK Biopharma Co. Ltd. Seoul 04763 South Korea

References (66)

Show source-provided references
1. 10.1016/S0092-8674(00)81683-910.1016/S0092-8674(00)81683-9 ↗
2. 10.1016/j.cell.2011.02.01310.1016/j.cell.2011.02.013 ↗
3. 10.1016/j.bcp.2013.11.01310.1016/j.bcp.2013.11.013 ↗
4. 10.1016/j.ccell.2020.12.00810.1016/j.ccell.2020.12.008 ↗
5. 10.1038/ncponc055810.1038/ncponc0558 ↗
6. 10.1128/MCB.8.8.321510.1128/MCB.8.8.3215 ↗
7. 10.1128/MCB.8.10.427010.1128/MCB.8.10.4270 ↗
8. 10.1128/MCB.25.14.6005-6020.200510.1128/MCB.25.14.6005-6020.2005 ↗
9. 10.1093/nar/gkq28610.1093/nar/gkq286 ↗
10. 10.3390/ijms2312636910.3390/ijms23126369 ↗
11. 10.1016/j.bbrc.2009.01.17210.1016/j.bbrc.2009.01.172 ↗
12. 10.1126/sciadv.add496910.1126/sciadv.add4969 ↗
13. 10.3390/ijms1910285210.3390/ijms19102852 ↗
14. 10.12717/DR.2020.24.4.24910.12717/DR.2020.24.4.249 ↗
15. 10.1016/j.gene.2004.08.01010.1016/j.gene.2004.08.010 ↗
16. Chae J. H. · Mol. Cells · 2003 · 15 · 4010.1016/S1016-8478(23)25235-8 ↗
17. 10.1073/pnas.100037410710.1073/pnas.1000374107 ↗
18. 10.3748/wjg.v17.i29.342010.3748/wjg.v17.i29.3420 ↗
19. 10.1016/j.celrep.2017.10.01710.1016/j.celrep.2017.10.017 ↗
20. 10.18632/oncotarget.1974110.18632/oncotarget.19741 ↗
21. 10.1016/S0925-4773(02)00046-110.1016/S0925-4773(02)00046-1 ↗
22. 10.1158/0008-5472.CAN-19-290810.1158/0008-5472.CAN-19-2908 ↗
23. Santhekadur P. K. · Am. J. Cancer Res. · 2012 · 2 · 269
24. 10.18632/oncotarget.1546210.18632/oncotarget.15462 ↗
25. 10.1111/j.1742-4658.2005.04564.x10.1111/j.1742-4658.2005.04564.x ↗
26. 10.1016/j.ab.2013.07.00110.1016/j.ab.2013.07.001 ↗
27. 10.1126/science.118305710.1126/science.1183057 ↗
28. 10.1073/pnas.090820110610.1073/pnas.0908201106 ↗
29. 10.1146/annurev.bi.47.070178.00222310.1146/annurev.bi.47.070178.002223 ↗
30. 10.1093/nar/gky19310.1093/nar/gky193 ↗
31. 10.1038/ncomms924410.1038/ncomms9244 ↗
32. 10.1038/cdd.2017.17210.1038/cdd.2017.172 ↗
33. 10.1038/s41586-019-1770-610.1038/s41586-019-1770-6 ↗
34. 10.1073/pnas.040228310110.1073/pnas.0402283101 ↗
35. 10.1038/387296a010.1038/387296a0 ↗
36. 10.1002/j.1460-2075.1993.tb05678.x10.1002/j.1460-2075.1993.tb05678.x ↗
37. 10.1038/nature0844410.1038/nature08444 ↗
38. 10.1038/ncb289710.1038/ncb2897 ↗
39. 10.1016/j.tig.2020.01.00110.1016/j.tig.2020.01.001 ↗
40. 10.1038/3504400510.1038/35044005 ↗
41. 10.1016/S0092-8674(00)80416-X10.1016/S0092-8674(00)80416-X ↗
42. 10.1016/j.cell.2009.04.05010.1016/j.cell.2009.04.050 ↗
43. 10.1158/2159-8290.CD-22-113110.1158/2159-8290.CD-22-1131 ↗
44. 10.1016/j.molcel.2011.06.01210.1016/j.molcel.2011.06.012 ↗
45. 10.1038/s12276-021-00590-210.1038/s12276-021-00590-2 ↗
46. 10.1021/acsmedchemlett.8b0022610.1021/acsmedchemlett.8b00226 ↗
47. 10.1021/bc800237t10.1021/bc800237t ↗
48. 10.1002/prca.20130010510.1002/prca.201300105 ↗
49. 10.1016/S0014-2999(02)02189-110.1016/S0014-2999(02)02189-1 ↗
50. 10.1056/NEJMoa070885710.1056/NEJMoa0708857 ↗
51. 10.1073/pnas.112160110910.1073/pnas.1121601109 ↗
52. 10.18632/oncotarget.465610.18632/oncotarget.4656 ↗
53. 10.1016/j.jphs.2019.10.00310.1016/j.jphs.2019.10.003 ↗
54. 10.1093/jmcb/mjz02610.1093/jmcb/mjz026 ↗
55. 10.1021/acs.jmedchem.8b0194510.1021/acs.jmedchem.8b01945 ↗
56. 10.1038/sj.onc.120717610.1038/sj.onc.1207176 ↗
57. 10.1016/j.cell.2017.11.00810.1016/j.cell.2017.11.008 ↗
58. 10.1038/s41588-022-01223-810.1038/s41588-022-01223-8 ↗
59. 10.1101/SQB.1985.050.01.07810.1101/SQB.1985.050.01.078 ↗
60. 10.1093/nar/gkw105610.1093/nar/gkw1056 ↗
61. 10.1177/088532821561250010.1177/0885328215612500 ↗
62. 10.1002/pro.390210.1002/pro.3902 ↗
63. 10.1002/cpbi.310.1002/cpbi.3 ↗
64. 10.1186/1471-2105-9-4010.1186/1471-2105-9-40 ↗
65. 10.1021/ja026939x10.1021/ja026939x ↗
66. 10.1016/S0195-5616(94)50004-410.1016/S0195-5616(94)50004-4 ↗